These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 37198990)
1. Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer. Elizabeth MS; Cristina SBJ; Christian CG Mini Rev Med Chem; 2024; 24(4):431-439. PubMed ID: 37198990 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Triple-Negative Breast Cancer. Emens LA Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294 [TBL] [Abstract][Full Text] [Related]
3. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142 [TBL] [Abstract][Full Text] [Related]
4. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related]
5. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Luo C; Wang P; He S; Zhu J; Shi Y; Wang J Front Oncol; 2022; 12():919072. PubMed ID: 35795050 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in triple-negative breast cancer. Katz H; Alsharedi M Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938 [TBL] [Abstract][Full Text] [Related]
7. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M; Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662 [TBL] [Abstract][Full Text] [Related]
8. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902 [TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Schettini F; Giuliano M; De Placido S; Arpino G Cancer Treat Rev; 2016 Nov; 50():129-141. PubMed ID: 27665540 [TBL] [Abstract][Full Text] [Related]
10. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. Sharmni Vishnu K; Win TT; Aye SN; Basavaraj AK BMC Cancer; 2022 Nov; 22(1):1139. PubMed ID: 36335316 [TBL] [Abstract][Full Text] [Related]
11. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Li CH; Karantza V; Aktan G; Lala M Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis. Zhang M; Song J; Yang H; Jin F; Zheng A Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538 [TBL] [Abstract][Full Text] [Related]
13. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. Chalakur-Ramireddy NKR; Pakala SB Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29298879 [TBL] [Abstract][Full Text] [Related]
14. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy Approaches for Breast Cancer Patients in 2023. Emens LA; Loi S Cold Spring Harb Perspect Med; 2023 Apr; 13(4):. PubMed ID: 37011999 [TBL] [Abstract][Full Text] [Related]
16. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725 [TBL] [Abstract][Full Text] [Related]
17. Progress and challenges of immunotherapy in triple-negative breast cancer. Zhu Y; Zhu X; Tang C; Guan X; Zhang W Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474 [TBL] [Abstract][Full Text] [Related]
18. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V; Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500 [TBL] [Abstract][Full Text] [Related]
19. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026 [TBL] [Abstract][Full Text] [Related]
20. Recent advances in targeted strategies for triple-negative breast cancer. Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]